X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (1980) 1980
Publication (120) 120
Book Chapter (25) 25
Book Review (17) 17
Dissertation (5) 5
Book / eBook (1) 1
Conference Proceeding (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (1122) 1122
oncology (1079) 1079
nonsmall cell lung cancer (891) 891
index medicus (779) 779
female (686) 686
male (674) 674
middle aged (608) 608
aged (598) 598
lung neoplasms - pathology (515) 515
lung cancer, non-small cell (510) 510
lung cancer (485) 485
chemotherapy (480) 480
cancer (459) 459
carcinoma, non-small-cell lung - pathology (406) 406
adult (395) 395
prognosis (368) 368
lung neoplasms - drug therapy (363) 363
carcinoma, non-small-cell lung - drug therapy (344) 344
survival (291) 291
nonsmall cell lung carcinoma (277) 277
lung neoplasms - genetics (275) 275
care and treatment (272) 272
research (269) 269
carcinoma (265) 265
neoplasm staging (256) 256
nonsmall cell (255) 255
aged, 80 and over (243) 243
lung neoplasms - mortality (227) 227
cisplatin (219) 219
carcinoma, non-small-cell lung - genetics (211) 211
carcinoma, non-small-cell lung - mortality (205) 205
treatment outcome (198) 198
expression (197) 197
respiratory system (196) 196
metastasis (192) 192
surgery (190) 190
tumors (185) 185
antineoplastic combined chemotherapy protocols - therapeutic use (176) 176
radiotherapy (176) 176
survival analysis (169) 169
survival rate (162) 162
adenocarcinoma (161) 161
abridged index medicus (159) 159
nonsmall cell lung (155) 155
health aspects (152) 152
lung neoplasms - metabolism (152) 152
mutation (150) 150
patient outcomes (147) 147
nonsmall-cell lung cancer (141) 141
gefitinib (138) 138
genetic aspects (135) 135
immunohistochemistry (135) 135
analysis (129) 129
antineoplastic agents - therapeutic use (127) 127
diagnosis (125) 125
lung neoplasms - surgery (124) 124
carcinoma, non-small-cell lung - metabolism (119) 119
development and progression (119) 119
retrospective studies (119) 119
carcinoma, non-small-cell lung - surgery (111) 111
gemcitabine (110) 110
therapy (108) 108
lung neoplasms - radiotherapy (106) 106
carcinoma, non-small-cell lung - radiotherapy (105) 105
animals (102) 102
lung neoplasms - therapy (101) 101
breast-cancer (96) 96
neoplasms. tumors. oncology. including cancer and carcinogens (96) 96
epidermal growth factor receptor (95) 95
lung neoplasms - diagnosis (95) 95
pathology (95) 95
randomized trial (95) 95
cell line, tumor (94) 94
gene expression (94) 94
cancer therapies (93) 93
non-small cell lung cancer (93) 93
risk factors (93) 93
radiology, nuclear medicine & medical imaging (92) 92
disease-free survival (90) 90
pharmacology & pharmacy (90) 90
apoptosis (89) 89
radiation-therapy (89) 89
usage (88) 88
carboplatin (87) 87
trial (85) 85
cell biology (84) 84
combined modality therapy (84) 84
paclitaxel (84) 84
erlotinib (83) 83
gene expression regulation, neoplastic (82) 82
carcinoma, non-small-cell lung - therapy (81) 81
follow-up studies (81) 81
medical prognosis (81) 81
growth-factor receptor (80) 80
drug therapy (79) 79
lung (79) 79
medicine, general & internal (79) 79
adenocarcinoma - pathology (78) 78
cell lung-cancer (78) 78
mutations (78) 78
more...
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (1956) 1956
French (22) 22
German (9) 9
Spanish (5) 5
Korean (4) 4
Chinese (3) 3
Czech (2) 2
Polish (2) 2
Hungarian (1) 1
Turkish (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


2005, Hematology/oncology clinics of North America, ISBN 9781416027737, Volume 19, no. 2., xii, p. 209-426
Book
Cancer, ISSN 0008-543X, 09/2008, Volume 113, Issue 6, pp. 1387 - 1395
BACKGROUND. The purpose of this study was to investigate whether tumor‐infiltrating immune cells in biopsy specimens can be used to predict the clinical... 
mast cell | macrophage | CD8+ T cell | stage IV | nonsmall cell lung cancer | Nonsmall cell lung cancer | Mast cell | Stage IV | CD8 | T cell | Macrophage | ANGIOGENESIS | CD8(+) T cell | MAST-CELLS | ENDOMETRIAL CANCER | BREAST-CANCER | CYTO-TOXICITY | ONCOLOGY | TUMOR-ASSOCIATED MACROPHAGES | PROGNOSTIC-SIGNIFICANCE | CARCINOMA | PROGRESSION | LYMPHOCYTES | Lung Neoplasms - drug therapy | CD8-Positive T-Lymphocytes - pathology | Prognosis | Lung Neoplasms - mortality | Stromal Cells - pathology | Humans | Middle Aged | Lung Neoplasms - pathology | Male | Antigens, CD - metabolism | Lymphocyte Activation - immunology | Carcinoma, Squamous Cell - mortality | Adult | Female | Macrophages - immunology | Carcinoma, Non-Small-Cell Lung - pathology | Mast Cells - immunology | Macrophages - pathology | Adenocarcinoma - immunology | Stromal Cells - immunology | Survival Rate | Adenocarcinoma - drug therapy | Carcinoma, Non-Small-Cell Lung - mortality | Carcinoma, Squamous Cell - immunology | Adenocarcinoma - secondary | Carcinoma, Non-Small-Cell Lung - immunology | Lung Neoplasms - immunology | Carcinoma, Squamous Cell - drug therapy | Lymphocytes, Tumor-Infiltrating - pathology | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Antigens, Differentiation, Myelomonocytic - metabolism | Mast Cells - pathology | Carcinoma, Squamous Cell - secondary | Aged | Carcinoma, Non-Small-Cell Lung - drug therapy | CD8-Positive T-Lymphocytes - immunology | Neoplasm Staging | Adenocarcinoma - mortality | Lymphocytes, Tumor-Infiltrating - immunology | Patient outcomes | CD8 lymphocytes | Physiological aspects | Research | Macrophages | Lung cancer, Non-small cell | Biological markers
Journal Article
Journal Article
Proceedings of the National Academy of Sciences of the United States of America, ISSN 0027-8424, 8/2010, Volume 107, Issue 35, pp. 15535 - 15540
The epidermal growth-factor receptor (EGFR) tyrosine kinase inhibitor erlotinib has been proven to be highly effective in the treatment of nonsmall cell lung... 
Vimentin | Cell motility | Secretion | Cell lines | Antibodies | Inflammation | Genetic mutation | Viability | Tumors | Lung neoplasms | Nonsmall cell lung cancer | Epidermal growth-factor receptor | GEFITINIB | ACTIVATION | epidermal growth-factor receptor | nonsmall cell lung cancer | MULTIDISCIPLINARY SCIENCES | SENSITIVITY | MUTATIONS | CELL-LINES | INTERLEUKIN-6 | INHIBITOR | EGFR | ERLOTINIB | Erlotinib Hydrochloride | Lung Neoplasms - drug therapy | Receptor, Epidermal Growth Factor - genetics | Epithelial Cells - metabolism | Humans | Drug Resistance, Neoplasm | Lung Neoplasms - pathology | Gene Expression Profiling | RNA Interference | Base Sequence | Gene Expression Regulation, Neoplastic - drug effects | Interleukin-6 - metabolism | Carcinoma, Non-Small-Cell Lung - pathology | Lung Neoplasms - genetics | Cell Line | Cell Survival - drug effects | Interleukin-6 - genetics | Carcinoma, Non-Small-Cell Lung - genetics | Epithelial Cells - pathology | Reverse Transcriptase Polymerase Chain Reaction | Cell Movement - drug effects | Transforming Growth Factor beta - pharmacology | Animals | Transforming Growth Factor beta - genetics | Interleukin-6 - pharmacology | Mice, Nude | Cell Line, Tumor | Mesoderm - metabolism | Mice | Protein Kinase Inhibitors - pharmacology | Carcinoma, Non-Small-Cell Lung - drug therapy | Mutation | Quinazolines - pharmacology | Mesoderm - pathology | Transforming Growth Factor beta - metabolism | Biological Sciences
Journal Article
International Journal of Cancer, ISSN 0020-7136, 05/2019, Volume 144, Issue 9, pp. 2227 - 2238
Vasculogenic mimicry (VM) is a special vascular pattern in malignant tumors, which is composed of highly aggressive tumor cells. This tumor cell‐mediated blood... 
plexinB1 | Sema4D | RhoA/ROCK signaling pathway | cell plasticity | vasculogenic mimicry | nonsmall cell lung cancer | PATHWAYS | ANGIOGENESIS | FASUDIL SUPPRESSES | RHO-KINASE | SEMAPHORIN 4D | EWING SARCOMA | IN-VITRO | ONCOLOGY | MELANOMA-CELLS | PROMOTES | PLASTICITY | RNA, Small Interfering - genetics | Semaphorins - antagonists & inhibitors | Humans | 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine - analogs & derivatives | Lung Neoplasms - pathology | rhoA GTP-Binding Protein - metabolism | Cell Movement - physiology | Antigens, CD - metabolism | Neovascularization, Pathologic - pathology | RNA Interference | rho-Associated Kinases - metabolism | Endothelial Cells - physiology | Carcinoma, Non-Small-Cell Lung - pathology | A549 Cells | Receptors, Cell Surface - metabolism | Semaphorins - metabolism | Nerve Tissue Proteins - genetics | Nerve Tissue Proteins - metabolism | Animals | Mice, Nude | 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine - pharmacology | Cell Line, Tumor | Mice | Mice, Inbred BALB C | Protein Kinase Inhibitors - pharmacology | Enzyme Activation | Receptors, Cell Surface - genetics | Lung cancer, Non-small cell | Lung cancer, Small cell | Metastasis | Leukocyte migration | Tumor cells | Lung cancer | Non-small cell lung carcinoma | RhoA protein | siRNA | Tissues | Blood | Endothelial cells | Rho-associated kinase | Mimicry | Metastases | Fibers | Angiogenesis | Signal transduction | Rocks | Inhibition | Axon guidance | Cell migration | Downstream | Cancer | Guanosinetriphosphatase | Tumors | Expression vectors
Journal Article
International Journal of Cancer, ISSN 0020-7136, 02/2010, Volume 126, Issue 3, pp. 743 - 755
We observed a 53% response rate in non‐small cell lung cancer (NSCLC) patients treated with vorinostat plus paclitaxel/carboplatin in a Phase I trial. Studies... 
paclitaxel | vorinostat | histone deacetylase | carboplatin | nonsmall cell lung cancer | Nonsmall cell lung cancer | Carboplatin | Histone deacetylase | Vorinostat | Paclitaxel | HDAC INHIBITOR | SAHA | SUBEROYLANILIDE HYDROXAMIC ACID | TUMOR-CELLS | OVARIAN-CANCER | historic deacetylase | GAMMA-H2AX FOCI | IN-VITRO | ONCOLOGY | DNA | ANTICANCER DRUGS | HISTONE DEACETYLASE INHIBITORS | Lung Neoplasms - drug therapy | Adenocarcinoma - pathology | Paclitaxel - pharmacology | Adenocarcinoma, Bronchiolo-Alveolar - pathology | Carcinoma, Squamous Cell - pathology | Humans | Histone Deacetylase Inhibitors - administration & dosage | Lung Neoplasms - pathology | Cell Line, Tumor - drug effects | Neoplasm Proteins - metabolism | Tubulin - metabolism | Cell Line, Tumor - pathology | Protein Processing, Post-Translational - drug effects | Hydroxamic Acids - administration & dosage | Paclitaxel - administration & dosage | Hydroxamic Acids - pharmacology | Carcinoma, Non-Small-Cell Lung - pathology | Tumor Stem Cell Assay | Carboplatin - administration & dosage | DNA, Neoplasm - drug effects | Drug Synergism | Acetylation - drug effects | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Histone Deacetylase Inhibitors - pharmacology | Carcinoma, Non-Small-Cell Lung - drug therapy | DNA Damage | Histones - metabolism | Carboplatin - pharmacology | Clinical Trials, Phase I as Topic | Index Medicus | non-small cell lung cancer
Journal Article
Journal of Cellular Biochemistry, ISSN 0730-2312, 03/2019, Volume 120, Issue 3, pp. 3765 - 3772
Journal Article
Cellular Physiology and Biochemistry, ISSN 1015-8987, 06/2017, Volume 42, Issue 1, pp. 346 - 356
Aim: The contribution of the inflammatory mediator interleukin-17 (IL-17) in nonsmall cell lung cancer (NSCLC) malignancy has been reported in the literature.... 
Nonsmall cell lung cancer | Vascular cell adhesion molecule 1 | Interleukin-17 | microRNA-181 | Proliferation | Migration | PHYSIOLOGY | METASTASIS | DOWN-REGULATION | POTENTIAL THERAPEUTIC TARGETS | CELL BIOLOGY | ADHESION MOLECULE-1 | TUMOR-MICROENVIRONMENT | IL-17 | NF-KAPPA-B | UP-REGULATION | EXPRESSION | T-CELLS | Cell Proliferation | MicroRNAs - antagonists & inhibitors | Humans | Lung Neoplasms - metabolism | Middle Aged | Lung Neoplasms - pathology | Male | MicroRNAs - metabolism | NF-kappa B - metabolism | Interleukin-17 - pharmacology | Case-Control Studies | RNA Interference | HEK293 Cells | Adult | Female | Vascular Cell Adhesion Molecule-1 - genetics | STAT3 Transcription Factor - genetics | STAT3 Transcription Factor - metabolism | Carcinoma, Non-Small-Cell Lung - pathology | Lung Neoplasms - genetics | NF-kappa B - antagonists & inhibitors | Carcinoma, Non-Small-Cell Lung - genetics | Carcinoma, Non-Small-Cell Lung - metabolism | Down-Regulation - drug effects | Vascular Cell Adhesion Molecule-1 - chemistry | Up-Regulation - drug effects | Interleukin-17 - metabolism | NF-kappa B - genetics | Cell Line, Tumor | Aged | MicroRNAs - genetics | Antagomirs - metabolism | STAT3 Transcription Factor - antagonists & inhibitors | Vascular Cell Adhesion Molecule-1 - metabolism | Cell Movement | Cytokines | Lung cancer | Metastasis | Gene expression | Cell adhesion & migration | Studies | Chemotherapy | Researchers | Medical prognosis | MicroRNAs | Rodents | Penicillin | Chronic obstructive pulmonary disease | Age | Smoking | Apoptosis
Journal Article
Journal Article